NO324472B1 - TNF-a-produksjonsinhibitore, farmasøytisk preparat og terapeutisk middel for inhibering av TNF-a-produksjon - Google Patents

TNF-a-produksjonsinhibitore, farmasøytisk preparat og terapeutisk middel for inhibering av TNF-a-produksjon Download PDF

Info

Publication number
NO324472B1
NO324472B1 NO20025718A NO20025718A NO324472B1 NO 324472 B1 NO324472 B1 NO 324472B1 NO 20025718 A NO20025718 A NO 20025718A NO 20025718 A NO20025718 A NO 20025718A NO 324472 B1 NO324472 B1 NO 324472B1
Authority
NO
Norway
Prior art keywords
tnf
production
compound
therapeutic agent
salt
Prior art date
Application number
NO20025718A
Other languages
English (en)
Norwegian (no)
Other versions
NO20025718L (no
NO20025718D0 (no
Inventor
Hiroshi Suhara
Hiroyuki Inoue
Masakazu Ban
Masato Horiuchi
Noriyoshi Yamamoto
Hiroshi Enomoto
Original Assignee
Santen Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Santen Pharmaceutical Co Ltd filed Critical Santen Pharmaceutical Co Ltd
Publication of NO20025718L publication Critical patent/NO20025718L/no
Publication of NO20025718D0 publication Critical patent/NO20025718D0/no
Publication of NO324472B1 publication Critical patent/NO324472B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/56—Amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/32—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40—Acylated substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/68—One oxygen atom attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
NO20025718A 2000-05-31 2002-11-28 TNF-a-produksjonsinhibitore, farmasøytisk preparat og terapeutisk middel for inhibering av TNF-a-produksjon NO324472B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2000162945 2000-05-31
PCT/JP2001/004586 WO2001092229A1 (fr) 2000-05-31 2001-05-31 Inhibiteurs de production de tnf-$g(a)

Publications (3)

Publication Number Publication Date
NO20025718L NO20025718L (no) 2002-11-28
NO20025718D0 NO20025718D0 (no) 2002-11-28
NO324472B1 true NO324472B1 (no) 2007-10-29

Family

ID=18666780

Family Applications (2)

Application Number Title Priority Date Filing Date
NO20025718A NO324472B1 (no) 2000-05-31 2002-11-28 TNF-a-produksjonsinhibitore, farmasøytisk preparat og terapeutisk middel for inhibering av TNF-a-produksjon
NO20073371A NO20073371L (no) 2000-05-31 2007-06-29 TNF-alfa-produksjonsinhibitorer

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO20073371A NO20073371L (no) 2000-05-31 2007-06-29 TNF-alfa-produksjonsinhibitorer

Country Status (15)

Country Link
US (5) US7098226B2 (OSRAM)
EP (4) EP1302461B1 (OSRAM)
JP (4) JP3867196B2 (OSRAM)
KR (2) KR100978304B1 (OSRAM)
CN (3) CN1307159C (OSRAM)
AT (4) ATE374186T1 (OSRAM)
AU (3) AU6067401A (OSRAM)
CA (2) CA2736344A1 (OSRAM)
CY (1) CY1107089T1 (OSRAM)
DE (4) DE60143098D1 (OSRAM)
DK (1) DK1302461T3 (OSRAM)
ES (4) ES2284138T3 (OSRAM)
NO (2) NO324472B1 (OSRAM)
PT (1) PT1302461E (OSRAM)
WO (1) WO2001092229A1 (OSRAM)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2284138T3 (es) * 2000-05-31 2007-11-01 Santen Pharmaceutical Co., Ltd. Inhibidores de la produccion de tnf-alfa para el tratamiento de enfermedades autoinmunes.
US7741346B2 (en) * 2001-11-30 2010-06-22 Santen Pharmaceutical Co., Ltd. Angiogenesis inhibitor
WO2003077847A2 (en) 2002-03-12 2003-09-25 Merck & Co., Inc. Substituted amides
US7456222B2 (en) 2002-05-17 2008-11-25 Sequella, Inc. Anti tubercular drug: compositions and methods
US20040033986A1 (en) 2002-05-17 2004-02-19 Protopopova Marina Nikolaevna Anti tubercular drug: compositions and methods
US7652039B2 (en) 2002-05-17 2010-01-26 Sequella, Inc. Methods of use and compositions for the diagnosis and treatment of infectious disease
WO2005034857A2 (en) 2003-09-05 2005-04-21 Sequella, Inc. Methods and compositions comprising diamines as new anti-tubercular therapeutics
WO2005102332A1 (ja) * 2004-04-27 2005-11-03 Santen Pharmaceutical Co., Ltd. 変形性関節症治療剤
WO2005102331A1 (ja) * 2004-04-27 2005-11-03 Santen Pharmaceutical Co., Ltd. 骨粗鬆症治療剤
UA87854C2 (en) * 2004-06-07 2009-08-25 Мерк Энд Ко., Инк. N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
WO2006035759A1 (ja) * 2004-09-27 2006-04-06 Santen Pharmaceutical Co., Ltd. 呼吸器疾患治療剤
WO2006035760A1 (ja) * 2004-09-27 2006-04-06 Santen Pharmaceutical Co., Ltd. 皮膚疾患治療剤
WO2006043518A1 (ja) * 2004-10-18 2006-04-27 Santen Pharmaceutical Co., Ltd. 神経疾患治療剤
KR101496206B1 (ko) * 2005-01-05 2015-02-27 애브비 인코포레이티드 11-베타-하이드록시스테로이드 데하이드로게나제 타입 1 효소의 억제제로서의 아다만틸 유도체
US20090192198A1 (en) 2005-01-05 2009-07-30 Abbott Laboratories Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
EP1846362A2 (en) * 2005-01-05 2007-10-24 Abbott Laboratories Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
US8562629B2 (en) * 2006-10-24 2013-10-22 Arthrocare Corporation Suture device having selective needle actuation and related method
EP1935420A1 (en) 2006-12-21 2008-06-25 Merck Sante 2-Adamantyl-butyramide derivatives as selective 11beta-HSD1 inhibitors
WO2009020603A2 (en) * 2007-08-08 2009-02-12 The Scripps Research Institute Upp amphiphilic alpha-helix mimetics
EP2666767A1 (en) * 2007-10-16 2013-11-27 Santen Pharmaceutical Co., Ltd. Therapeutic agent for TRPV1-mediated disease
CN102196810B (zh) * 2008-10-22 2013-11-06 参天制药株式会社 改善肠吸收性的药物组合物
RU2404157C1 (ru) * 2009-02-16 2010-11-20 Государственное образовательное учреждение высшего профессионального образования Волгоградский государственный технический университет (ВолгГТУ) Способ получения n-(1-адамантилалкил)циклоалкиламинов
HRP20090186A2 (hr) 2009-03-31 2010-10-31 Institut Ruđer Bošković Adamantanski bisureidni derivati, metoda priprave i primjena u detekciji aniona
US8357939B2 (en) * 2009-12-29 2013-01-22 Siltronic Ag Silicon wafer and production method therefor
MX2016006325A (es) 2013-11-15 2016-12-02 Wistar Inst Inhibidores del antígeno nuclear 1 de epstein-barr, y su método de uso.
KR102616818B1 (ko) 2015-05-14 2023-12-22 더 위스타 인스티튜트 오브 아나토미 앤드 바이올로지 Ebna1 억제제 및 그의 사용 방법
CN112543634A (zh) 2018-05-17 2021-03-23 威斯达研究所 Ebna1抑制剂晶体形式及其制备和使用方法
CN110423216B (zh) * 2019-08-26 2021-01-05 浙江工业大学 一种2-(1-金刚烷甲酰胺基)乙基甲酸酯类化合物及其制备方法和应用
CN120303251A (zh) * 2022-10-21 2025-07-11 伊泽阿恩埃免疫疗法股份有限公司 可电离脂质

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2640055A (en) * 1951-01-06 1953-05-26 Warner Hudnut Inc Amides
CH509314A (de) * 1967-02-16 1971-06-30 Shimamoto Takio Verfahren zur Herstellung von Pyridinmethylcarbamaten
US3682922A (en) * 1969-01-16 1972-08-08 Searle & Co N-acyl-n-{8 (n{40 ,n{40 -disubstituted amino)-alkyl{9 -1-adamantylmethylamines
US4724235A (en) 1981-05-20 1988-02-09 A. H. Robins Company, Incorporated N-(arylthioalkyl)-N'-(aminoalkyl)ureas useful in the treatment of arrhythmia
US4597902A (en) * 1981-05-20 1986-07-01 A. H. Robins Company, Incorporated N-(arylthioalkyl)-N'-(aminoalkyl)ureas
US4555515A (en) * 1985-02-25 1985-11-26 Stauffer Chemical Co. Pyridylpropyl carbamates as insect repellents
US5599944A (en) * 1987-03-24 1997-02-04 Bayer Aktiengesellschaft Intermediates for herbicidal sulphonylaminocarbonyltriazolinones having substituents which are bonded via sulphur
US5776963A (en) * 1989-05-19 1998-07-07 Hoechst Marion Roussel, Inc. 3-(heteroaryl)-1- (2,3-dihydro-1h-isoindol-2-yl)alkyl!pyrrolidines and 3-(heteroaryl)-1- (2,3-dihydro-1h-indol-1-yl)alkyl!pyrrolidines and related compounds and their therapeutic untility
FR2664269B1 (fr) * 1990-07-05 1992-10-02 Roussel Uclaf Nouveaux derives n-substitues d'alpha-mercapto alkylamines, leur procede de preparation, leur application a titre de medicaments et les compositions les renfermant.
US5173506A (en) 1990-08-16 1992-12-22 Schering Corporation N-(mercaptoalkyl)ureas and carbamates
JPH06501708A (ja) * 1990-11-06 1994-02-24 スミスクライン・ビーチャム・コーポレイション イミダゾリジノン化合物
NZ242054A (en) * 1991-03-22 1993-11-25 British Tech Group Pyridine derivatives having a bridged alicyclic group; medicaments
GB9401129D0 (en) 1994-01-21 1994-03-16 British Bio Technology Hydroxamic acid derivatives as metalloproteinase inhibitors
ES2223049T3 (es) * 1994-04-29 2005-02-16 Pfizer Inc. Amidas aciclicas y ciclicas novedosas como estimuladores de la liberacion de neurotransmisores.
CA2502764A1 (en) 1995-08-22 1997-03-06 Japan Tobacco Inc. Amide compounds
GB9526558D0 (en) * 1995-12-27 1996-02-28 Fujisawa Pharmaceutical Co Heterobicyclic derivatives
GB9526560D0 (en) * 1995-12-27 1996-02-28 Bayer Ag Use of 2-Amino-Heterocycles
EP0880511A4 (en) * 1996-01-16 1999-06-16 Merck & Co Inc Integrin receptor antagonists
IT1283637B1 (it) 1996-05-14 1998-04-23 Italfarmaco Spa Composti ad attivita' antinfiammatoria ed immunosoppressiva
EP0948489A1 (en) * 1996-12-17 1999-10-13 Fujisawa Pharmaceutical Co., Ltd. Piperazine compounds as inhibitors of mmp or tnf
ATE228590T1 (de) 1997-09-17 2002-12-15 Chemiefaser Lenzing Ag Verfahren zur behandlung von cellulosefasern
EP0903434B1 (de) 1997-09-17 2002-11-27 Lenzing Aktiengesellschaft Verfahren zur Behandlung von Cellulosefasern
JP3603177B2 (ja) 1998-03-26 2004-12-22 参天製薬株式会社 新規ウレア誘導体
CA2325741C (en) 1998-03-26 2007-05-08 Santen Pharmaceutical Co., Ltd. Urea derivatives having tnf- .alpha. production inhibitory effects
JP3472917B2 (ja) 1998-08-05 2003-12-02 参天製薬株式会社 含窒素芳香族複素環を有する新規ウレア誘導体
EP1103543A4 (en) 1998-08-05 2005-06-22 Santen Pharmaceutical Co Ltd NOVEL UREA DERIVATIVES CONTAINING NITROGENIC AROMATIC HETEROCYCLES
CA2362705A1 (en) * 1999-03-19 2000-09-28 Joseph B. Santella, Iii N-adamant-1-yl-n'-¬4-chlorobenzothiazol-2-yl| urea useful in the treatment of inflammation and as an anticancer radiosensitizing agent
KR20010112408A (ko) 1999-04-07 2001-12-20 모리타 다카카즈 Ｎ-치환되고-Ｎ'-치환된 우레아 유도체 및 ＴＮＦ-α 생성억제제로서의 그의 용도
DE29910780U1 (de) * 1999-06-21 1999-09-16 Hahn Schickard Ges Halte- und Betätigungsvorrichtung
ES2284138T3 (es) * 2000-05-31 2007-11-01 Santen Pharmaceutical Co., Ltd. Inhibidores de la produccion de tnf-alfa para el tratamiento de enfermedades autoinmunes.
US7741346B2 (en) 2001-11-30 2010-06-22 Santen Pharmaceutical Co., Ltd. Angiogenesis inhibitor

Also Published As

Publication number Publication date
NO20073371L (no) 2002-11-28
CN1307159C (zh) 2007-03-28
NO20025718L (no) 2002-11-28
ATE374186T1 (de) 2007-10-15
CA2409741A1 (en) 2001-12-06
EP1568692B1 (en) 2010-09-15
NO20025718D0 (no) 2002-11-28
ATE358122T1 (de) 2007-04-15
US7923461B2 (en) 2011-04-12
ATE481385T1 (de) 2010-10-15
ES2284138T3 (es) 2007-11-01
AU2006200864A1 (en) 2006-03-23
EP1302461B1 (en) 2007-09-26
US20060241155A1 (en) 2006-10-26
CA2409741C (en) 2011-11-01
DE60127595T2 (de) 2008-01-10
ES2339141T3 (es) 2010-05-17
AU2001260674B2 (en) 2006-03-30
KR20030007762A (ko) 2003-01-23
DE60127595D1 (de) 2007-05-10
EP1743885A2 (en) 2007-01-17
EP1743885A3 (en) 2007-03-14
JP4482735B2 (ja) 2010-06-16
WO2001092229A1 (fr) 2001-12-06
DE60130658D1 (de) 2007-11-08
EP1561749B1 (en) 2007-03-28
CN1432000A (zh) 2003-07-23
KR20080093166A (ko) 2008-10-20
PT1302461E (pt) 2007-12-13
US20080182881A1 (en) 2008-07-31
CY1107089T1 (el) 2012-10-24
AU2006200864B2 (en) 2007-12-06
US7098226B2 (en) 2006-08-29
EP1561749A1 (en) 2005-08-10
DE60143098D1 (de) 2010-10-28
JP3867196B2 (ja) 2007-01-10
CN1590374A (zh) 2005-03-09
KR100880698B1 (ko) 2009-02-02
CA2736344A1 (en) 2001-12-06
US20060229342A1 (en) 2006-10-12
US20030032623A1 (en) 2003-02-13
JP2010059204A (ja) 2010-03-18
ES2293993T3 (es) 2008-04-01
EP1302461A4 (en) 2004-05-26
JP2010059205A (ja) 2010-03-18
ATE448204T1 (de) 2009-11-15
US7345064B2 (en) 2008-03-18
EP1302461A1 (en) 2003-04-16
JP2002053555A (ja) 2002-02-19
CN1324012C (zh) 2007-07-04
CN1590375A (zh) 2005-03-09
DK1302461T3 (da) 2008-01-28
US7491739B2 (en) 2009-02-17
CN1284771C (zh) 2006-11-15
DE60130658T2 (de) 2008-01-31
EP1568692A1 (en) 2005-08-31
KR100978304B1 (ko) 2010-08-26
JP2006213739A (ja) 2006-08-17
EP1743885B1 (en) 2009-11-11
DE60140495D1 (de) 2009-12-24
US20100016380A1 (en) 2010-01-21
AU6067401A (en) 2001-12-11
ES2353020T3 (es) 2011-02-24

Similar Documents

Publication Publication Date Title
NO324472B1 (no) TNF-a-produksjonsinhibitore, farmasøytisk preparat og terapeutisk middel for inhibering av TNF-a-produksjon
TWI290927B (en) 2-Acetoxy-5-(alpha-cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine acid-additive salts
RU2434851C1 (ru) Циклические n, n'-диарилтиомочевины или n, n'-диарилмочевины - антагонисты андрогенных рецепторов, противораковое средство, способ получения и применения
WO2004041276A1 (ja) 酢酸アニリド誘導体を有効成分とする過活動膀胱治療剤
WO2010126002A1 (ja) ヘテロ環スルホンアミド化合物を含有する医薬
AU2021296833A1 (en) Cereblon binding compounds, compositions thereof, and methods of treatment therewith
BR112020005064A2 (pt) aminas beta-hidróxi heterocíclicas e seu uso no tratamento de hiperglicemia
JP2004067635A (ja) Ｄｇａｔ阻害剤
RS53138B (sr) 4-[2-(4-metilfenilsulfanil)fenil] piperidin za lečenje sindroma nadraženih creva (ibs).
NO321606B1 (no) Pyrrolderivater og medisinsk sammensetning
CN105611930A (zh) 作为非凋亡调控性细胞死亡抑制剂的螺环喹喔啉衍生物
CN112313233A (zh) Jak家族激酶的小分子抑制剂
WO2024060911A1 (zh) 苯并异噻唑化合物及其药物组合物和应用
WO2010098286A1 (ja) ミネラルコルチコイド受容体拮抗薬を含有する医薬
US20150368195A1 (en) Indoline compounds for treatment and/or prevention of inflammation diseases
TW314467B (OSRAM)
WO2021229519A1 (en) Sterols in the treatment and/or prevention of sars-cov-2 infection
WO2021242758A1 (en) Improved nitro-fatty acid oral dose regimens
JPWO2014129513A1 (ja) 潰瘍性大腸炎の予防または治療剤と新規フラーレン誘導体
EP2599767A1 (en) Phenylbutyl-derivatives
WO2011058943A1 (ja) Ｍｃｈ ｒ１アンタゴニスト活性を有する化合物とｎｐｙ ｙ５受容体アンタゴニスト活性を有する化合物を組み合わせてなる医薬組成物
KR102247408B1 (ko) 피마살탄 프로드러그
JP5807767B2 (ja) 便秘症の予防又は治療薬
TW201032805A (en) Pharmaceutical compositions comprising a compound having suppressive effect on nutrient digestion or absorption and a cyclohexanecarboxamide derivative
HU203839B (en) Process for producing pharmaceutical composition containing acrylic acid derivatives

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: AYUMI PHARMACEUTICAL CORPORATION, JP

CREP Change of representative

Representative=s name: BRYN AARFLOT AS, POSTBOKS 449 SENTRUM, 0104 OSLO

CREP Change of representative

Representative=s name: ZACCO NORWAY AS, POSTBOKS 2003 VIKA, 0125 OSLO

MM1K Lapsed by not paying the annual fees